<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Contraception: Hormonal contraceptive vaginal rings</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Contraception: Hormonal contraceptive vaginal rings</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Contraception: Hormonal contraceptive vaginal rings</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Kerns, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip D Darney, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney A Schreiber, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H25167569"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Combined (estrogen-progestin) hormonal contraception is available as an oral pill (ie, oral contraceptive or OC), transdermal patch, or vaginal ring. All are user-controlled and are safe and highly effective when used consistently and correctly. They have approximately the same benefits and risks, but vaginal rings have the advantage of longer duration of action than other combined methods. Commonly available combined hormonal contraceptive rings include the one-month etonogestrel/ethinyl estradiol ring (ENG/EE, sample brand names NuvaRing, EluRyng) and the one-year segesterone acetate/ethinyl estradiol ring (SA/EE, sample name Annovera). The hormonal contraceptive vaginal rings have the advantage of avoiding difficulty with daily or weekly use. This topic will review the indications, contraindications, side effects, and use of hormonal contraceptive vaginal rings.</p><p>Related content on contraceptive counseling and method selection and estrogen-progestin combined contraceptives is presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.</p><p class="headingAnchor" id="H28791938"><span class="h1">DESCRIPTION AND STRUCTURE</span></p><p class="headingAnchor" id="H1754001290"><span class="h2">Etonogestrel and ethinyl estradiol ring</span><span class="headingEndMark"> — </span>The etonogestrel/ethinyl estradiol (ENG/EE, sample names NuvaRing, EluRyng, Haloette, EnilloRing) ring is a flexible device measuring 54 mm in diameter and 4 mm in cross-section that is worn vaginally for three weeks and then removed (and discarded) for one week  (<a class="graphic graphic_picture graphicRef85785" href="/d/graphic/85785.html" rel="external">picture 1</a>) [<a href="#rid1">1-3</a>]. The outer ring is composed of both ethinyl estradiol (EE) and an ethylene vinyl acetate copolymer that contains crystals of ENG, the 3-keto-metabolite of desogestrel. The device releases an average of 120 mcg/day of ENG and 15 mcg/day of EE over 21 days of use [<a href="#rid1">1,4</a>]. The device is latex-free. </p><p>There is an immediate increase in serum hormonal concentration after insertion with a slow decrease over the cycle [<a href="#rid5">5</a>]. The concentration of EE is lower with the ENG/EE vaginal ring compared with other combined hormonal contraceptives:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, the maximum serum concentration of EE was 30 percent lower than desogestrel-containing oral contraceptives (OCs; 34.7±17.5 ng/L versus 124.9±46.3 ng/L) and systemic exposure to EE was half that of desogestrel-containing OCs [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial comparing a levonorgestrel-containing OC, transdermal patch, and ENG/EE vaginal ring, users of the ENG/EE vaginal ring experienced 3.4 times lower EE exposure than patch users and 2.1 times lower EE exposure than OC users [<a href="#rid5">5</a>]. Exposure to EE in the ENG ring, OC, and patch groups were 10.6±2.5 ng-h/mL, 21.9±2.9 ng-h/mL, and 35.8±5.5 ng-h/mL, respectively. These differences were not all proportional to differences in EE dose of the three contraceptives: 30 mcg/day for the OC, 20 mcg/day for the patch, and 15 mcg/day for the ENG ring.</p><p></p><p>Unlike OCs where the peak concentration of the progestin occurs daily, the ENG/EE vaginal ring reaches its peak ENG concentration once per cycle, within seven days of insertion. Systemic exposure to ENG (as determined by area-under-the-curve) is similar for the ENG vaginal ring and desogestrel-containing OCs [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H1966310785"><span class="h2">Segesterone and ethinyl estradiol ring</span><span class="headingEndMark"> — </span>The one-year reusable segesterone acetate/ethinyl estradiol (SA/EE, sample name Annovera) ring is 56 mm in overall diameter and 8.4 mm in cross-sectional diameter [<a href="#rid6">6</a>]. The ring is worn for three weeks and removed for one week, and that pattern is repeated for a total of 13 cycles. This pattern of use results in regular withdrawal bleeding and an overall pooled unintended pregnancy rate (Pearl index) of 2.98 per 100 woman-years. The ring contains two internal channels: one channel with both SA and EE and the other channel with SA only. The device releases approximately 150 mcg/day of SA and 13 mcg/day of EE over the 21-day use period. The inactive ingredients include silicone elastomers, titanium dioxide, dibutyltin dilaurate, and silicone medical adhesive. The device is latex-free. The median T<sub>max</sub> of both hormones is approximately 2 hours after vaginal insertion; concentrations become more constant approximately 96 hours after insertion. Other product advantages include that it does not require refrigeration for storage and that it is not orally active, which may appeal to lactating people who want to avoid exposing their infants to progestin. This one-year ring is approved by the US Food and Drug Administration and available for use.</p><p class="headingAnchor" id="H16531250"><span class="h1">CANDIDATES AND SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H3138207842"><span class="h2">Candidates</span><span class="headingEndMark"> — </span>People who desire highly effective, reversible, noncoitally dependent contraception and who have no contraindications to taking estrogen or progestins are candidates for the vaginal ring. The United States <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=16682" target="_blank">Centers of Disease Control and Prevention (CDC)</a> and the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Bjsessionid%3D5D751537449E125CDDB5D7BCE1948DB6%3Fsequence%3D1&amp;token=ys4ssl%2FUvi0Bo1i8AhIZhBCXcFZ2z3DUjevaOmV3edlSHKAfzczCgdzsJ9oXDzSz20KV3ywktE2VrDtIs1%2FAPyY4ylKKlhZyzi23LSpJNQJ37ODZJ9H1gsxmaU5RLmOb64fAFvgK9yQstdajVw%2BIOutNLtYWEMItVRKlWeW%2FJXU%3D&amp;TOPIC_ID=16682" target="_blank">World Health Organization</a> have published medical eligibility criteria for people with various medical conditions and personal characteristics who desire an estrogen-progestin contraceptive. The combined hormonal rings provide the same benefits of combined oral contraceptive (OC) pills, including contraception, regulation of bleeding, endometrial protection, and, in some, reduction of dysmenorrhea and endometriosis-related pain. In addition, the ring is a good option for people who want the benefits of combined OCs but prefer to avoid a method that requires daily user compliance [<a href="#rid7">7,8</a>]. </p><p>The noncontraceptive benefits, risks, and side effects of combined estrogen-progestin contraceptives are reviewed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p></p><p class="headingAnchor" id="H433943634"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>People who should not use combined estrogen-progestin contraceptives, including vaginal contraceptive rings, include those with [<a href="#rid1">1,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A high risk of arterial or venous thromboembolic disease, including those over age 35 who smoke</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Estrogen- or progestin-sensitive cancer, including breast cancer</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver tumors or disease, particularly with abnormal liver function tests</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Undiagnosed or abnormal uterine bleeding</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Likely or confirmed pregnancy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis C who are taking drug combinations containing ombitasvir/paritaprevir/<a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>, with or without dasabuvir</p><p></p><p class="headingAnchor" id="H831183380"><span class="h2">Use in special contexts</span><span class="headingEndMark"> — </span>Information regarding estrogen-progestin contraceptive use in individuals with specific medical issues can be found through the United States <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=16682" target="_blank">Centers of Disease Control and Prevention (CDC)</a> and the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Bjsessionid%3D5D751537449E125CDDB5D7BCE1948DB6%3Fsequence%3D1&amp;token=ys4ssl%2FUvi0Bo1i8AhIZhBCXcFZ2z3DUjevaOmV3edlSHKAfzczCgdzsJ9oXDzSz20KV3ywktE2VrDtIs1%2FAPyY4ylKKlhZyzi23LSpJNQJ37ODZJ9H1gsxmaU5RLmOb64fAFvgK9yQstdajVw%2BIOutNLtYWEMItVRKlWeW%2FJXU%3D&amp;TOPIC_ID=16682" target="_blank">World Health Organization</a>. Commonly encountered distinct populations include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adolescence</strong> – Vaginal contraceptive rings are a good option for adolescents [<a href="#rid9">9</a>]. Use of a vaginal ring can be more private than OCs and the transdermal patch. Compared with the depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> injection, another contraceptive method that is popular with adolescents, vaginal rings offer the benefits of a combined hormonal method: shorter, lighter, and less painful periods, no association with weight gain, and no adverse effect on bone mineral density. Contraception selection for adolescents is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/107.html" rel="external">"Contraception: Issues specific to adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity</strong> – Theoretically, contraceptive efficacy of combined hormonal contraceptives may be lower in obese individuals. (See  <a class="medical medical_review" href="/d/html/5470.html" rel="external">"Contraception: Counseling for females with obesity", section on 'Contraceptive ring'</a>.)</p><p></p><p class="bulletIndent1">Data on use of the hormonal contraceptive rings in people with body mass index (BMI) ≥30 are sparse as the initial etonogestrel/ethinyl estradiol (ENG/EE) clinical trials did not include such people and the segesterone acetate/ethinyl estradiol (SA/EE) trials excluded this subpopulation after two participants with BMI &gt;29 developed venous thromboembolisms [<a href="#rid1">1,6</a>]. Thus, it is not known if the contraceptive efficacy of the hormonal rings is reduced in those with BMI ≥30. However, preliminary data do not indicate any increased risk or decreased efficacy.</p><p></p><p class="bulletIndent1">There are limited data on efficacy or venous thromboembolism risk in obese individuals who use contraceptive rings. Most studies of obesity assess the impact of combined oral hormonal contraception [<a href="#rid10">10,11</a>]. The United States <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=16682" target="_blank">Centers of Disease Control and Prevention (CDC)</a> lists all combined estrogen-progestin contraceptives as Group 2 (advantages generally outweigh theoretical or proven risks) for obese individuals but does not provide subgroup recommendations by type of combined contraceptive or obesity class. </p><p></p><p class="bulletIndent1">More information on contraceptive selection for obese individuals can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/5470.html" rel="external">"Contraception: Counseling for females with obesity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum and lactation</strong> – Nonlactating postpartum people with no other contraindications to combined estrogen-progestin contraceptives can use the contraceptive vaginal ring, although initiation is delayed until 21 days postpartum or more to reduce the risk of thromboembolic events [<a href="#rid12">12,13</a>]. Although there are conflicting data on the impact of combined hormonal contraception on lactation, lactating individuals are generally advised to delay contraceptive vaginal ring insertion until 30 days postpartum. (See  <a class="medical medical_review" href="/d/html/6708.html" rel="external">"Contraception: Postpartum counseling and methods"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postabortion</strong> – For those with no other contraindications, combined hormonal contraceptives, including the contraceptive vaginal ring, can be started after first- or second-trimester abortions [<a href="#rid12">12,13</a>]. While the ENG/EE and SA/EE manufacturers advise people who undergo second-trimester abortion to wait four weeks before initiating the contraceptive vaginal ring (because of increased risk of venous thromboembolism), the CDC supports initiating combined hormonal contraception within seven days of the procedure, including the same day [<a href="#rid1">1,6,13</a>]. (See  <a class="medical medical_review" href="/d/html/109209.html" rel="external">"Contraception: Postabortion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perimenopause</strong> – Individuals over age 35 can use contraceptive vaginal rings if they do not have additional risk factors for cardiovascular or thromboembolic disease (eg, hypertension, diabetes, dyslipidemia, and obesity) [<a href="#rid6">6</a>]. </p><p></p><p class="headingAnchor" id="H2755544833"><span class="h1">COUNSELING POINTS</span><span class="headingEndMark"> — </span>In addition to discussing the contraceptive benefits with patients, we discuss the efficacy, side effects, potential complications, and noncontraceptive benefits below. </p><p class="headingAnchor" id="H3285826272"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>Combined hormone vaginal contraceptive rings are highly effective at preventing pregnancy when used consistently and correctly  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). For the etonogestrel/ethinyl estradiol (ENG/EE) ring, the failure rate, defined as the number of pregnancies per 100 woman-years of exposure in the first year of use, is equivalent to that of oral contraceptives (OCs) and the patch (0.3 percent for perfect use and 9 percent for typical use)  (<a class="graphic graphic_table graphicRef120134" href="/d/graphic/120134.html" rel="external">table 1</a>) [<a href="#rid14">14,15</a>]. For the segesterone acetate/ethinyl estradiol (SA/EE) ring, the unintended pregnancy rate is nearly 3 per 100 person-years based on pooled data from over 2000 participants including over 17,400 cycles [<a href="#rid6">6</a>]. Ovulation also appears to be suppressed with off-label five- and six-week ring use [<a href="#rid16">16-18</a>]. Typical use effectiveness is lower than that for methods that are less user-dependent (eg, intrauterine contraception and implants).</p><p>Studies specific to each ring type include:</p><p class="bulletIndent1"><span class="glyph">●</span>For the ENG/EE ring:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a noncomparative study of 2322 participants from Europe and North America, the efficacy of the ENG/EE vaginal ring was 99.1 percent [<a href="#rid8">8</a>]. Over half of the pregnancies (11 in 21) were attributable to compliance problems. North American participants experienced more pregnancies than their European counterparts, perhaps because a greater percentage of North American participants were new contraceptive users instead of switchers from another method (59 versus 38 percent), and more reported that they removed the ring during intercourse.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized trial in college students found that those assigned to the ENG/EE vaginal ring reported more perfect use in the first two months compared with OC users, but differences were not statistically significant in the third month [<a href="#rid19">19</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the SA/EE ring, in a multicenter study that included over 2200 participants, the unintended pregnancy rate was 2.98 (95% CI 2.13-4.06) per 100 person-years [<a href="#rid20">20</a>]. The ring was more than 97.5 percent effective in Kaplan-Meier analysis. More than one-half of the participants completed up to 13 cycles. Of the 290 participants followed after ring discontinuation, all had resumption of menses, or pregnancy as desired, within six months. </p><p></p><p>For both ring types, the principal mechanism of contraceptive action is inhibition of ovulation [<a href="#rid6">6,16,17,21</a>]. Other contributory mechanisms include thickening of cervical mucus, which prevents penetration of sperm into the upper genital tract, inhibition of sperm capacitation, and slowing of tubal motility [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Mechanisms of action'</a>.)</p><p class="headingAnchor" id="H2569148812"><span class="h2">Side effects</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic</strong> – Systemic side effects from the vaginal rings are generally similar to those of combined estrogen-progestin OCs [<a href="#rid23">23-27</a>]. Breast tenderness and nausea (estrogen-related side effects) are reported less often by vaginal ring users than OC users, a finding that is consistent across three trials comparing the varying ethinyl estradiol (EE) doses and different progestins [<a href="#rid23">23-25</a>]. No differences in headache [<a href="#rid23">23-25</a>] or weight gain [<a href="#rid26">26,28,29</a>] are seen across studies comparing ring users with OC users. Ring use is not associated with clinically significant metabolic effects (eg, changes in blood pressure, blood chemistries, lipid levels, carbohydrate metabolism, thyroid function, hematological indices) [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local</strong> – Ring users report more vaginitis, vaginal wetness, and leukorrhea compared with OC users [<a href="#rid15">15,23,25-27</a>]. In a meta-analysis of trials comparing the ENG/EE vaginal ring with various estrogen-progestin contraceptive pills, the odds of vaginitis were approximately 2.5 times greater (odds ratios [OR] 2.48 to 2.84) and the odds of leukorrhea were three to six times greater (OR 3.21 to 6.42) for those using the contraceptive ring [<a href="#rid15">15</a>]. These symptoms did not result in discontinuation of the ring nor did they require treatment.</p><p></p><p class="bulletIndent1">Although the contraceptive ring appears to alter vaginal discharge, contraceptive ring users do not appear to have an increased risk of acquiring vaginal or cervical infections, including human immunodeficiency virus and human papilloma virus, although supporting data are partly derived from studies of OCs and other vaginal rings [<a href="#rid30">30-35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unscheduled bleeding</strong> – The vaginal ring provides cycle control equivalent or superior to OCs and the transdermal patch [<a href="#rid26">26,36,37</a>]. Compared with an extended cycle regimen of contraceptive pills, the traditional 28-day ENG/EE ring cycle has a lower number of unscheduled bleeding days but a higher total number of bleeding/spotting days. A study of people using a continuous or 364-day ring cycle reported a median of zero bleeding days and 10 spotting days during the first three months of extended use; by comparison, for those using a 28-day ring cycle, the median number of bleeding and spotting days was 7.5 and 8, respectively [<a href="#rid38">38</a>]. Acceptability of continuous use is high, even with unscheduled bleeding [<a href="#rid38">38-40</a>]. For people who are bothered by this bleeding but otherwise benefit from continuous use, instituting a four-day ring-free period can improve their symptoms [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/5474.html" rel="external">"Evaluation and management of unscheduled bleeding in individuals using hormonal contraception", section on 'Estrogen-progestin contraceptives'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mood</strong> – Data on the impact of combined estrogen-progestin OCs, which are often used as a proxy for the estrogen-progestin vaginal rings, on mood disorders are conflicting [<a href="#rid41">41-44</a>]. Specific to the ENG/EE vaginal ring, a trial of 188 participants comparing depressive symptoms among those using the contraceptive ring or a levonorgestrel-containing OC pill reported no differences in depressive symptoms for ring users at cycles 6 (OR 0.31, 95% CI 0.08-1.19) and 12 (OR 0.23, 95% CI 0.05-1.03) [<a href="#rid15">15</a>]. A different trial of 201 participants initiating either the ENG/EE vaginal ring or a triphasic norgestimate-containing OC reported that ring users were more likely to report no change in mood while OC users were more likely to report worsening mood [<a href="#rid24">24</a>]. Given that the data do not support an association between mood and use of the contraceptive vaginal ring, universal counseling is not necessary. For patients who are concerned about mood changes, providers should use a patient-centered approach and counsel that mood could improve, decline, or stay the same after initiating use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone mineral density</strong> – There is no evidence that the rings have an adverse effect on bone mineral density, although data are limited. One randomized trial compared markers of bone formation and resorption as well as bone mineral density between ENG/EE ring users, patch users, and controls and reported no differences by method or compared with controls [<a href="#rid45">45</a>]. </p><p></p><p class="headingAnchor" id="H1886455783"><span class="h2">Serious complications</span><span class="headingEndMark"> — </span>The combined hormonal vaginal rings carry the same risks as other combined hormonal methods. There are limited data specifically about the rings, and recommendations regarding safety come mostly from studies of OCs. The United States <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=16682" target="_blank">Centers for Disease Control and Prevention's Medical Eligibility Criteria for Contraceptive Use</a> is a useful guide for evaluating the safety of contraceptive methods, including vaginal rings, for particular patients. </p><p class="headingAnchor" id="H2149314335"><span class="h3">Cardiovascular and thromboembolic events</span><span class="headingEndMark"> — </span>Use of combined hormonal (estrogen-progestin) contraceptives (CHCs), including pills, patch, and rings, increases the risk of thromboembolic events over that of nonusers [<a href="#rid1">1,6</a>]. For comparison, the risk of having a venous thrombotic event (VTE), per 10,000 individuals, is 1 to 5 for non-CHC users and 3 to 12 for CHC users. However, the VTE risk does not appear to be higher for ring users compared with users of other combined estrogen-progestin OCs. Similar to combined OCs, cases of stroke, both arterial and venous, thrombotic and hemorrhagic, as well as myocardial infarction have been reported in contraceptive ring users [<a href="#rid46">46-49</a>]. </p><p>Examples of representative studies for the ENG/EE ring include:</p><p class="bulletIndent1"><span class="glyph">●</span>A 15-year Danish historical cohort study evaluated data from national registries to determine the risk of arterial events, thrombotic stroke, and myocardial infarction in users and nonusers of hormonal contraception [<a href="#rid46">46</a>]. The cohort included the entire population of Danish individuals identifying as women aged 15 to 49 years for the period 1995 through 2009. During over 38,000 person-years of ENG/EE contraceptive vaginal ring use, thrombotic strokes occurred more often in users than nonusers (31.4 versus 24.2 per 100,000 person years) for an adjusted relative risk of 2.5 (95% CI 1.41-4.41) near the lower range of the increased risk for combined oral contraceptives. The number of myocardial infarctions in ENG/EE ring users was too low to provide reliable estimates of relative risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2013 multicenter analysis from the United States and several European sites compared venous and arterial thromboembolism risk among new users of the ENG/EE ring and new users of combined OCs [<a href="#rid50">50</a>]. In this study, which included over 66,000 woman-years of contraceptive use, ring users were not at greater risk of VTE or arterial thromboembolism than users of combined OCs containing a variety of progestins and low dose EE (VTE incidence for ring and OC users: 8.3 and 9.2 per 10,000 person-years, respectively; arterial thromboembolism 2.2 and 2.8 per 10,000 person-years, respectively). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2013 cohort study of over 570,000 individuals from the United States identifying as women initiating combined hormonal contraception reported no increase in venous or arterial thrombotic events among those initiating the ENG/EE contraceptive ring compared with those initiating one of four low-dose comparator combined OCs (relative hazard total mortality for ATE and VTE 0.96, 95% CI 0.29-3.14) [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2017 systematic review of three studies comparing ENG/EE ring users with users of combined OCs containing <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> noted mixed outcomes; one cohort study reported an elevated rate ratio for VTE, while a case-control and different cohort study reported no difference in VTE risk [<a href="#rid52">52</a>]. </p><p></p><p>The relative and absolute cardiovascular and thromboembolic risks of combined estrogen-progestin OC, including the impact of differing estrogen doses and progestin types, is reviewed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="headingAnchor" id="H299122129"><span class="h3">Toxic shock</span><span class="headingEndMark"> — </span>Rare cases of toxic shock syndrome have been reported in ENG/EE contraceptive ring users [<a href="#rid22">22</a>]. No cases of toxic shock syndrome occurred during the clinical trials for the SA/EE ring [<a href="#rid6">6</a>]. Causation has not been proven and may have been related to concurrent tampon use. (See  <a class="medical medical_review" href="/d/html/3161.html" rel="external">"Staphylococcal toxic shock syndrome"</a> and  <a class="medical medical_review" href="/d/html/3162.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H518356273"><span class="h2">Noncontraceptive benefits</span><span class="headingEndMark"> — </span>Estrogen-progestin contraceptives, including vaginal rings, have several noncontraceptive benefits  (<a class="graphic graphic_table graphicRef82147" href="/d/graphic/82147.html" rel="external">table 2</a>). Details specific to the vaginal ring include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cycle control and bleeding reduction</strong> – While cycle control is a benefit of all combined hormonal contraceptive methods, vaginal rings provide cycle control that is at least equivalent, and possibly superior, to OCs and the transdermal patch based on studies of the ENG/EE ring [<a href="#rid26">26,36,37</a>]. Several studies have reported that ENG/EE ring users are less likely than users of monophasic or triphasic OCs to experience breakthrough bleeding, especially in the first few months of use [<a href="#rid25">25-27,37,53,54</a>]. Prolonged or frequent bleeding [<a href="#rid37">37</a>] and early or late withdrawal bleeding [<a href="#rid25">25</a>] are also less likely among ring users. There were no differences in bleeding patterns between those just starting hormonal contraception or those switching to the ENG/EE ring [<a href="#rid55">55</a>]. An improvement in cycle control has been demonstrated among individuals who switch from OC or transdermal patch to the ENG/EE vaginal ring [<a href="#rid56">56</a>]. </p><p></p><p class="bulletIndent1">In addition, contraceptive ring users have reductions in bleeding volume and duration similar to that of OC users. A trial comparing the ENG/EE contraceptive ring with oral norethisterone in 95 participants with idiopathic heavy menstrual bleeding reported a 2/3 reduction in bleeding volume and three day reduction in bleeding duration after three cycles of use [<a href="#rid57">57</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduction of endometriosis pain</strong> – The contraceptive ring appears to reduce endometriosis-related pain. A cohort study comparing the ENG/EE vaginal ring with the transdermal patch for treatment of persistent endometriosis pain reported that both treatments reduced dysmenorrhea [<a href="#rid36">36</a>]. Ring users were more satisfied with their treatment than patch users (72 versus 48 percent). (See  <a class="medical medical_review" href="/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Estrogen-progestin contraceptives'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less impact on insulin resistance</strong> – Woman at risk for, or diagnosed with, insulin resistance may benefit from the contraceptive ring compared with OCs. One prospective observational study comparing the contraceptive ring users with estrogen-progestin OC users reported the ring had no impact on insulin resistance while OC use increased insulin levels [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Improved psychosexual function</strong> – Although there are conflicting data on the impact of the contraceptive ring on sexual function, the overall body of evidence suggests improved sexual functioning [<a href="#rid25">25,59-61</a>]. </p><p></p><p class="headingAnchor" id="H1915199283"><span class="h2">Acceptability</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Satisfaction</strong> – Most individuals find the vaginal ring a highly acceptable form of contraception because it is easy to use, remains effective if removal or reinsertion are not performed precisely on time, results in low systemic hormone levels, and is rapidly effective and reversible.</p><p></p><p class="bulletIndent1">Studies of the ENG/EE ring have reported high satisfaction rates (84 to 96 percent) and high likelihood of recommending the method to a friend (87 to 98 percent) [<a href="#rid8">8,55,56</a>]. People like the method's ease of use, once-a-month administration, and low dose of hormones (vaginal hormone delivery increases bioavailability) [<a href="#rid23">23,62</a>]. Less than 3 percent of individuals report ring expulsion, feeling the ring, or coital problems [<a href="#rid55">55</a>]. Vaginal ring users are as satisfied, or more satisfied, than OC users [<a href="#rid23">23,24</a>]. Satisfaction with the SA/EE ring is similar to that of the ENG/EE ring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuation</strong> – Discontinuation of combined hormonal contraceptive methods is common. Studies of the ENG/EE ring reported that 28 to 35 percent of people discontinued the vaginal ring before one year, and most discontinuations occurred in the first three to four cycles. Although side effects are the most commonly reported reason for discontinuing a contraceptive method, they only accounted for 11 to 30 percent of the ENG/EE ring users discontinuations [<a href="#rid8">8,23,54-56,63</a>]. </p><p></p><p class="bulletIndent1">While one trial reported that ring users overall were less likely to discontinue the method than OC users (12 versus 22 percent) [<a href="#rid25">25</a>], another trial reported no difference in discontinuation rate by method [<a href="#rid19">19</a>]. A trial including 201 participants comparing the vaginal ring with a norgestimate-containing OC reported that among those using the "quick start" method, ring users were less likely to discontinue than OC users (11 versus 16 percent) [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent1">As with all hormonal contraceptives, providing or prescribing up to a one-year supply of contraception enhances convenience and continuation of the method.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Correct use</strong> – Correct and consistent use of the vaginal ring is similar to that with OCs. Individuals in ENG/EE clinical trials report following recommended use of the vaginal ring (three weeks in, one week out) in approximately 80 to 90 percent of cycles [<a href="#rid23">23,54</a>]. Many report altering use of the vaginal ring by prolonging the ring-free period (more than seven days) [<a href="#rid8">8,53,55</a>] and extending use up to five weeks to regulate their cycles [<a href="#rid62">62</a>]. For both the ENG/EE and SA/EE rings, cultural factors may play a role, as one study showed that North American participants were less likely (80 versus 91 percent) than their European counterparts to use the ring correctly (eg, failing to replace it within three hours after removal) [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H3346269380"><span class="h1">ADMINISTRATION AND USE</span></p><p class="headingAnchor" id="H16531257"><span class="h2">Health screening and pregnancy exclusion</span><span class="headingEndMark"> — </span>Ideally, blood pressure should be measured before initiation of combined hormonal contraceptives; physical examination and laboratory tests are not necessary [<a href="#rid13">13</a>]. However, in settings where access to health care is limited, it is reasonable to initiate use of the ring without blood pressure documentation. (See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Screening requirements'</a>.) </p><p>Similar to oral contraceptives, contraceptive rings can be started anytime during the cycle once pregnancy has been reasonably excluded  (<a class="graphic graphic_table graphicRef67567" href="/d/graphic/67567.html" rel="external">table 3</a>). The patient can insert the ring on the same-day they are seen or delay start to the onset of the next menstrual period  (<a class="graphic graphic_algorithm graphicRef56863" href="/d/graphic/56863.html" rel="external">algorithm 1</a>). If the date of last menses was more than 7 days prior (etonogestrel/ethinyl estradiol [ENG/EE] ring), more than 5 days prior (segesterone acetate/ethinyl estradiol [SA/EE] ring) or is uncertain, we advise the patient to use a back-up method of contraception (eg, male or female condom) for the first seven days of ring use. Of note, the ENG/EE manufacturer advises using a back-up method if the ring is inserted any time other than the first day of menses [<a href="#rid64">64</a>], while the United States Centers for Disease Control and Prevention (CDC) recommends back-up if it is inserted &gt;5 days from the beginning of menstrual bleeding [<a href="#rid13">13</a>]. However, there is evidence that ring insertion initiated as many as 10 days after the beginning of the last menstrual period does not compromise ovulation inhibition [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H914438024"><span class="h2">Insertion and use</span><span class="headingEndMark"> — </span>The vaginal ring requires a prescription, but does not need to be fitted. Both the ENG/EE and SA/EE rings are available in one size and are self-administered  (<a class="graphic graphic_picture graphicRef85785" href="/d/graphic/85785.html" rel="external">picture 1</a>). For people using a different contraceptive method, the approach to starting to the contraceptive ring is presented in the table  (<a class="graphic graphic_table graphicRef77410" href="/d/graphic/77410.html" rel="external">table 4</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insertion</strong> – To insert, the individual should choose a comfortable position  (<a class="graphic graphic_figure graphicRef85977" href="/d/graphic/85977.html" rel="external">figure 2</a>). The sides of the ring are pressed together, and then it is inserted into the vagina as high as possible for comfort and to prevent it from falling out  (<a class="graphic graphic_figure graphicRef85546" href="/d/graphic/85546.html" rel="external">figure 3</a>). The position of the ring does not affect contraceptive efficacy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of use and removal</strong> – Both the ENG/EE and SA/EE rings are left in place for three weeks and then removed for a single ring-free week to allow withdrawal bleeding [<a href="#rid1">1</a>]. People using the ENG/EE ring discard the ring whereas those using the SA/EE ring remove it, wash it with mild soap and water, dry it with a clean cloth, and store the ring in its case [<a href="#rid1">1,2,6</a>]. As the SA/EE ring is used repeatedly for thirteen total cycles, the manufacturer advises writing the initiation and anticipated discard dates on the case so the product is not used longer than intended.</p><p></p><p class="bulletIndent1">During the three weeks of use, people should periodically check to ensure the ring is in place, although the optimal timing or frequency is not known [<a href="#rid65">65</a>]. To begin a new cycle for either ring type, a new ring should be inserted on the same day of the week that the old ring was removed the previous week (ie, if the ring was removed on a Monday, a new ring should be inserted on the following Monday). The ring should not be removed during intercourse. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>In event of delayed removal</strong> – If the ENG/EE ring has been in place more than 3 but ≤5 weeks, it is removed, and a new one is inserted after a one-week ring-free interval. Alternately, patients can immediately insert a new ENG/EE ring without using a one-week ring-free interval, although they may have breakthrough bleeding (see the menstrual suppression bullet below). If the ring has been in place for &gt;5 weeks, the old ring is removed, a new ENG/EE ring is inserted, <strong>and</strong> back-up contraception (eg, male or female condom) is advised until the new ring has been in place for seven days. The ENG/EE ring contains sufficient steroids to maintain stable blood hormone concentrations for a five-week period of time [<a href="#rid17">17</a>]. Thus, inhibition of ovulation is sufficiently maintained if a user forgets to remove the ring after the usual three-week use period. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>In event of delayed insertion</strong> – The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6504a1.htm%3Fs_cid%3Drr6504a1_w&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDUG08ZbGAJiu0qbyu%2F2zoI9S6tDFFGkqrofEu6x4BLSnjAf2YtkLNeW%2BABX%2FWfw0wprhImEEGXBTJh4uBFC8ZY%3D&amp;TOPIC_ID=16682" target="_blank">US Selected Practice Recommendations for Contraceptive Use</a> provides an algorithm for counseling patients who delay insertion or reinsertion of the ring  (<a class="graphic graphic_algorithm graphicRef89824" href="/d/graphic/89824.html" rel="external">algorithm 2</a>) [<a href="#rid13">13</a>]. For people who have delayed insertion of a new ring or reinsertion of a current ring for less than 48 hours, they should reinsert the ring immediately and remove it at the regularly scheduled time. No additional contraception is required. People who have delayed ring insertion or reinsertion for 48 hours or more should also immediately insert the ring as soon as possible <strong>and </strong>use a second method of contraception, such as condoms. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuous use for menstrual suppression</strong> – Data supporting continuous ring use for menstrual suppression come from studies of the ENG/EE ring. People who desire fewer days of withdrawal bleeding and are willing to tolerate some spotting can safely use an extended ring regimen whereby the prior ENG/EE ring is removed and a new ring is immediately inserted every three weeks, which omits the hormone-free week and resultant withdrawal bleeding for up to one year [<a href="#rid38">38,40,66-68</a>]. Extended use is effective and does not worsen bothersome side effects, except for unscheduled bleeding [<a href="#rid38">38,40</a>]. </p><p></p><p class="bulletIndent1">Data supporting continuous use of the SA/EE ring are not yet available, but continuous use (ie, no time break between yearly ring removal and replacement) is clinically reasonable. As with the ENG/EE ring, patients are counseled about possible increase in unscheduled bleeding. (See <a class="local">'Side effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Broken ring</strong> – Rarely, the contraceptive ring may break at the weld joint [<a href="#rid1">1</a>]. Although the break does not impact the contraceptive effectiveness, it may make the ring more likely to slip out, which will reduce efficacy. In the event of a broken ring, the broken ring should be removed and new ring inserted. </p><p></p><p class="headingAnchor" id="H241440395"><span class="h2">Reinsertion after unintended removal or expulsion</span><span class="headingEndMark"> — </span>Unplanned removal (eg, with removing a tampon) or expulsion (eg, during a bowel movement) of the contraceptive ring can occur. If it accidentally falls out, it may be rinsed with cool or warm (not hot) water and reinserted into the vagina. Instructions for reinsertion timing and need for back-up contraception vary by ring type. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>For the ENG/EE ring</strong> – If the ENG/EE ring is out of the vagina for less than three hours, no additional steps are needed [<a href="#rid1">1</a>]. If the ring remains out for more than three consecutive hours, subsequent steps depend on the week of the cycle that the ring is out [<a href="#rid69">69</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>During the first two weeks of the cycle, the ring is reinserted as soon as possible [<a href="#rid1">1</a>]. Pregnancy may not be prevented if the ring is out for more than three hours during this time, so an additional form of contraception, such as condoms with spermicide, is used until the reinserted ring has been in place for seven continuous days. The ring should subsequently be removed according to the original schedule, after which the individual can expect to have their normal period.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>During week 3 of the cycle, discard the ring, then choose one of two different restart options [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Option one – Insert a new ring and begin a new three-week cycle. Back-up contraception or abstinence is recommended until the new ring has been used continuously for seven days. The individual may not have a regular period until they reach their next ring-free week or they may have vaginal spotting or bleeding prior to then.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Option two – This option is only used if the prior ring was in place for seven consecutive days. Leave the ring out for up to seven days. During this ring-free time the individual may have their period. By day seven, insert a new ring and begin a new cycle. Back-up contraception or abstinence is recommended until the new ring has been used continuously for seven days.</p><p></p><p class="bulletIndent1">In contrast to the above approach, the CDC takes the more liberal stance that back-up contraception is not needed if reinsertion of the current ring occurs in less than 48 hours  (<a class="graphic graphic_algorithm graphicRef89824" href="/d/graphic/89824.html" rel="external">algorithm 2</a>) [<a href="#rid13">13</a>]. There is evidence that ovulation is inhibited when the ring has been in place for only three days [<a href="#rid16">16</a>]; however, there are no data about actual failure rates after only three days of use, so a back-up method is recommended for one week.</p><p></p><p class="bulletIndent1">If the ring has been out of the vagina for an unknown amount of time, then pregnancy should be excluded prior to reinsertion of the ring  (<a class="graphic graphic_table graphicRef67567" href="/d/graphic/67567.html" rel="external">table 3</a>) [<a href="#rid65">65</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For the SA/EE ring</strong> – If the SA/EE ring is expelled or removed for up to two hours, the ring is reinserted after washing it with mild soap and water and drying it [<a href="#rid6">6</a>]. No additional contraception is needed. If the SA/EE ring is out of the vagina for two continuous hours or more, or more than two cumulative hours (multiple episodes that add up to two hours), then the ring is cleaned and reinserted, and back-up contraception (eg, male condoms) is used for an additional seven consecutive days. </p><p></p><p class="headingAnchor" id="H495210680"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>A routine follow-up examination is unnecessary, but blood pressure should be checked yearly, if possible. The individual should contact their provider if they have concerns about the method, want to discontinue contraception or switch to another method, or have changes in health status that might affect the appropriateness of use of an estrogen-progestin contraceptive [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H16530872"><span class="h2">Return of fertility</span><span class="headingEndMark"> — </span>Most people resume ovulation and regular menstrual cycles within a month after stopping contraceptive rings [<a href="#rid1">1</a>]. A study of 45 participants using the ENG/EE contraceptive ring reported that, after removal of the vaginal ring, the median time to ovulation was 19 days and earliest ovulation occurred after 13 days [<a href="#rid70">70</a>]. In the initial trials of the SA/EE ring, all 290 participants who desired pregnancy or switched to a nonhormonal method resumed menses within six months of discontinuation [<a href="#rid6">6</a>]. Those who desire pregnancy can attempt to conceive whenever they are ready.</p><p class="headingAnchor" id="H4208038818"><span class="h2">Use with other vaginal devices and products</span><span class="headingEndMark"> — </span>The contraceptive ring can interfere with other female barrier contraceptives [<a href="#rid65">65,71</a>]. For example, the diaphragm, cervical cap, or female condom should be not be used as back-up contraception with the contraceptive rings [<a href="#rid1">1</a>]. Tampons may be used during menses as they do not impact hormone absorption from the rings, which are typically not in place during the time frame of vaginal bleeding [<a href="#rid1">1</a>]. Water-based vaginal lubricants and spermicides are compatible with the combined contraceptive rings, but oil-based products (including silicone-based lubricants) are not [<a href="#rid1">1,6</a>]. </p><p class="headingAnchor" id="H2954349834"><span class="h1">DRUG INTERACTIONS</span></p><p class="headingAnchor" id="H1302035920"><span class="h2">Systemic medications</span><span class="headingEndMark"> — </span>Combined hormonal vaginal rings can interact with other systemic medications to both increase and decrease each other's levels. Much of the available information is based upon combined oral contraceptive (OC) pills. (See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Drug interactions'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduced estrogen/progestin levels</strong> – Information on medication interactions that may reduce contraceptive ring estrogen and progestin levels is mostly based on studies of OC pills. Drugs that increase liver microsomal enzyme activity may decrease systemic exposure to the estrogen and progestins in contraceptive vaginal rings, and thus potentially decrease contraceptive efficacy. Such medications include <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a>, barbiturates, <a class="drug drug_general" data-topicid="9254" href="/d/drug information/9254.html" rel="external">bosentan</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, <a class="drug drug_general" data-topicid="8934" href="/d/drug information/8934.html" rel="external">felbamate</a>, <a class="drug drug_general" data-topicid="8502" href="/d/drug information/8502.html" rel="external">griseofulvin</a>, <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>, <a class="drug drug_general" data-topicid="9518" href="/d/drug information/9518.html" rel="external">rufinamide</a>, <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>, and products containing St. John's wort [<a href="#rid1">1,6</a>]. In addition, reduced systemic estrogen and progestin levels have been noted with the HIV protease inhibitors <a class="drug drug_general" data-topicid="9685" href="/d/drug information/9685.html" rel="external">nelfinavir</a>, <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>, <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and <a class="drug drug_general" data-topicid="9459" href="/d/drug information/9459.html" rel="external">tipranavir</a>/ritonavir as well as the Hepatitis C protease inhibitors boceprevir and telaprevir. The non-nucleoside reverse transcriptase inhibitor <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a> may also reduce systemic hormone levels. We advise individuals who require these medications to use an additional form of contraception (ie, backup contraception such as male condoms) or consider an alternate contraceptive method. (See  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Altered levels of other medications</strong> – Combined hormonal contraceptives (CHCs) can decrease plasma <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> levels [<a href="#rid12">12,13</a>]. People who require both medications are advised to have their lamotrigine levels monitored. CHCs are also avoided in those using Hepatitis C medications ombitasvir/paritaprevir/<a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>, with or without dasabuvir, due to potential for ALT elevations [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use with emergency contraception</strong> – The additional use of combined estrogen-progestin emergency contraception is not advised during segesterone acetate/ethinyl estradiol (SA/EE) ring use (eg, in event of ring expulsion for &gt;2 hours) [<a href="#rid6">6</a>] Guidance for the etonogestrel/ethinyl estradiol (ENG/EE) ring is not available. Both the SA/EE and ENG/EE rings can be started after emergency contraception is used. (See  <a class="medical medical_review" href="/d/html/5475.html" rel="external">"Emergency contraception"</a>.)</p><p></p><p class="headingAnchor" id="H3496361226"><span class="h2">Use with vaginal medications</span><span class="headingEndMark"> — </span>Water-based vaginal drugs, such as for the treatment of vaginal candidiasis or bacterial vaginosis, are compatible with the vaginal contraceptive rings [<a href="#rid1">1,6</a>]. However, the oil-based <a class="drug drug_general" data-topicid="16763" href="/d/drug information/16763.html" rel="external">miconazole</a> suppositories have been associated with increased hormone levels [<a href="#rid1">1,6</a>]. Thus, particularly for individuals using the SA/EE ring, only water-based or oral therapies are advised.</p><p class="headingAnchor" id="H28792047"><span class="h1">NEW DEVELOPMENTS IN VAGINAL RINGS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nestorone and ethinyl estradiol combined hormonal vaginal ring</strong> – The Population Council is studying vaginal rings containing estrogen (ethinyl estradiol [EE] or 17-beta-estradiol [E2]) and Nestorone (NES), a potent 19-nor-testosterone derivative that is not orally active, but is an effective contraceptive when administered via implants, transdermal systems, and rings [<a href="#rid72">72-75</a>]. NES does not bind to androgen or estrogen receptors and thus can potentially minimize some hormone-related side effects, such as acne. Three studies of long-acting (13 cycles) rings containing NES/EE reported efficacy and acceptability similar to other short-acting contraceptives [<a href="#rid73">73-75</a>]. As EE induces production of hepatic proteins and clotting factors [<a href="#rid76">76</a>], an E2/NES ring was created with the goal of providing a novel contraceptive method that did not appear to increase thrombogenic risk (based on studies in a postmenopausal population) [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progesterone-releasing vaginal ring</strong> – The Progering is a progesterone-releasing vaginal ring for lactating individuals. It is available in parts of South America and Africa [<a href="#rid77">77</a>]. Each ring releases 10 mg of <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> daily and lasts for four months [<a href="#rid77">77,78</a>], although it is approved for only three months of use. A ring that releases a synthetic progestin (Nesterone) is under development.</p><p></p><p class="bulletIndent1">Progesterone-only rings function primarily by thickening cervical mucus to prevent sperm penetration but also inhibit ovulation and endometrial receptivity. Progesterone-only rings may be less effective over the long-term than rings containing both a progestin and an estrogen but are still highly effective among breastfeeding individuals since breastfeeding provides some protection from pregnancy [<a href="#rid79">79</a>]. Unscheduled bleeding, which is a common side effect of all progestin-only methods, is less likely to occur in breastfeeding individuals because of prolonged lactational amenorrhea [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1">The <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> vaginal ring contains 22.5 percent progesterone dispersed in silicone. The system delivers 10 mg/day of the physiological hormone progesterone, but due to its homogeneous design, serum levels decline during its three-month duration of use [<a href="#rid81">81</a>]. A Phase 3 trial demonstrated that it has high contraceptive efficacy (98.5 percent) and safety [<a href="#rid81">81</a>]. Despite its effectiveness and application for lactating individuals, the progesterone vaginal ring has not yet become popular [<a href="#rid82">82</a>].</p><p></p><p class="headingAnchor" id="H3563271979"><span class="h1">RESOURCES FOR PATIENTS AND CLINICIANS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fbedsider.org%2F&amp;token=zJ5gQ3rEz%2FWfF96g4EN6dZ0WWANDd0amr7%2FGWBeQMYA%3D&amp;TOPIC_ID=16682" target="_blank">bedsider.org</a> – A free website developed by the National Campaign to Prevent Teen and Unplanned Pregnancy, a private nonprofit group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.choiceproject.wustl.edu%2F&amp;token=%2BnVJmPhZ7CoZ6P5TTscsQMEfRjhRSH%2BHYjLFHmNv8MpZBNOY80TFEfWmQJ4v5GVF&amp;TOPIC_ID=16682" target="_blank">CHOICE Project</a> – A free website sponsored by the Washington University School of Medicine in St. Louis that provides resources on contraceptive options and training resources for clinicians.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fyoungwomenshealth.org%2F&amp;token=4ZVQuaw7JPQhsSQn2msmz4V2t0hJWr2nmfMP%2FLbrjZq3BOM8pXRApS0zZOoQmNVZ&amp;TOPIC_ID=16682" target="_blank">Center for Young Women's Health</a> – A free website run by Boston Children's Hospital that addresses reproductive health needs of teens and young adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sexandu.ca%2F&amp;token=vdCs7dqmABYrTYLl86e3UBvZDVaCgDBYOgHXgKrHwtk%3D&amp;TOPIC_ID=16682" target="_blank">SexandU.ca</a> – An educational site run by the Society of Obstetricians and Gynaecologists of Canada that includes descriptions of various methods and a tool to help with selection of birth control.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.plannedparenthood.org%2F&amp;token=xXI%2By9QNEPjV52%2B%2BDeHAeZ9SXc2ukqt22nAmmnoIhbmjKCcbIKeiWKTXDj94bQ%2F4&amp;TOPIC_ID=16682" target="_blank">Planned Parenthood</a> – A nonprofit organization dedicated to reproductive health with resources for patients and clinicians.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2FPatients&amp;token=IQxLzDq4doJGUgaZgeIY0609e6kP88t%2BkfEnsFxRTPcTSb1%2BMcd%2F6nq0xBC60AQD&amp;TOPIC_ID=16682" target="_blank">ACOG Contraceptive FAQs</a> – American College of Obstetricians and Gynecologists addresses frequently asked questions (FAQs) about contraception.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6503a1.htm%3Fs_cid%3Drr6503a1_w&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDUG08ZbGAJiu0qbyu%2F2zoIMVxNz7qTN91sychfwmBjXnjAf2YtkLNeW%2BABX%2FWfw04tcvgAO1wSmuCs3zXaWpQk%3D&amp;TOPIC_ID=16682" target="_blank">United States Medical Eligibility Criteria for Contraceptive Use</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6503a1.htm%3Fs_cid%3Drr6503a1_w&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDUG08ZbGAJiu0qbyu%2F2zoIMVxNz7qTN91sychfwmBjXnjAf2YtkLNeW%2BABX%2FWfw04tcvgAO1wSmuCs3zXaWpQk%3D&amp;TOPIC_ID=16682" target="_blank">United States Selected Practice Recommendations for Contraceptive Use</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.who.int%2Freproductivehealth%2Fpublications%2Ffamily_planning%2FMEC-5%2Fen%2F&amp;token=am3d6Dtogt5e88ewNpT1YCltU%2FEFMr%2BhAi4SPVAemsTKqzf2ZgfGe43nM5ICIgmhJ4qumfr5y6dKOrL%2BzojbSN1MkmGldk6kwM6nQNxB6GA%3D&amp;TOPIC_ID=16682" target="_blank">World Health Organization Medical Eligibility Criteria for Contraceptive Use</a></p><p></p><p class="headingAnchor" id="H1043171054"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112268.html" rel="external">"Society guideline links: Contraception"</a>.)</p><p class="headingAnchor" id="H348041351"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16162.html" rel="external">"Patient education: Hormonal birth control (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/8419.html" rel="external">"Patient education: Hormonal methods of birth control (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13061038"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ring types</strong> – There are two contraceptive vaginal rings. The first consists of an outer ring composed of ethinyl estradiol (EE) and an ethylene vinyl acetate copolymer that contains crystals of etonogestrel (ENG), a metabolite of desogestrel (sample names NuvaRing, EluRyng, Haloette, EnilloRing). The second vaginal ring contains segesterone acetate/ethinyl estradiol (SA/EE) and provides contraception for one year (sample name Annovera). (See <a class="local">'Description and structure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Vaginal rings are a highly effective method of contraception when used consistently and correctly  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). The failure rate, defined as the number of pregnancies per 100 woman-years of exposure in the first year of use, is equivalent to that of oral contraceptives (OCs) and the patch (0.3 percent for perfect use and 9 percent for typical use). The unintended pregnancy rate for the SA/EE ring appears to be closer to 3 percent. (See <a class="local">'Efficacy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates</strong> – Appropriate candidates for vaginal ring contraception are people desiring contraception with no contraindications to estrogen or progestin therapy. The <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=16682" target="_blank">Centers of Disease Control and Prevention</a> and the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Bjsessionid%3D5D751537449E125CDDB5D7BCE1948DB6%3Fsequence%3D1&amp;token=ys4ssl%2FUvi0Bo1i8AhIZhBCXcFZ2z3DUjevaOmV3edlSHKAfzczCgdzsJ9oXDzSz20KV3ywktE2VrDtIs1%2FAPyY4ylKKlhZyzi23LSpJNQJ37ODZJ9H1gsxmaU5RLmOb64fAFvgK9yQstdajVw%2BIOutNLtYWEMItVRKlWeW%2FJXU%3D&amp;TOPIC_ID=16682" target="_blank">World Health Organization</a> have published medical eligibility criteria for people with various medical conditions and personal characteristics who desire an estrogen-progestin contraceptive. (See <a class="local">'Candidates and special populations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – Systemic side effects from the vaginal rings are generally similar to those of combined estrogen-progestin OCs. In contrast to OC users, ring users report more local (vaginal) symptoms, including vaginitis, wetness, and leukorrhea. However, these symptoms do not require treatment and generally do not result in ring discontinuation. (See <a class="local">'Side effects'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular risk</strong> – While the risk of cardiovascular and thrombotic events is increased in ring users compared with nonusers of combined hormonal contraception, the risk does not appear to be higher compared with users of other combined hormonal contraceptives. (See <a class="local">'Cardiovascular and thromboembolic events'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prior to initiation</strong> – Prior to starting the contraceptive vaginal ring, blood pressure should be measured and pregnancy should be reasonably excluded. Physical examination and laboratory tests are not necessary. (See <a class="local">'Health screening and pregnancy exclusion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ring prescription and use</strong> – The vaginal ring requires a prescription, but does not need to be fitted. Both rings are available in one size and is self-administered. (See <a class="local">'Administration and use'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ENG/EE ring</strong> – For the ENG/EE ring, the ring is left in place for three weeks and then removed and discarded. No ring is in place for a single ring-free week. To begin a new cycle, a new ring is inserted on the same day of the week that the old ring was removed the previous week (ie, if the ring was removed on a Monday, a new ring should be inserted on the following Monday). The ring does not need to be removed during sexual intercourse, but may be removed for up to three hours without affecting contraceptive efficacy. (See <a class="local">'Insertion and use'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SA/EE ring</strong> – For the SA/EE ring, the ring is also worn for three weeks and then removed for one ring-free week. However, the ring is not discarded but is washed and stored in its case for reinsertion for the next cycle [<a href="#rid6">6</a>]. As the SA/EE ring is used repeatedly for thirteen total cycles, the manufacturer advises writing the initiation and anticipated discard dates on the case so the product is not used longer than intended. (See <a class="local">'Insertion and use'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unplanned removal or expulsion</strong> – Unplanned removal or expulsion of the contraceptive ring can occur. If it accidentally falls out, it may be rinsed with cool or warm (not hot) water and reinserted into the vagina. Subsequent steps, including need for back-up contraception, depend on the number of hours without the ring and the week of the cycle (for the ENG/EE ring only). (See <a class="local">'Reinsertion after unintended removal or expulsion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resumption of fertility</strong> – Fertility returns within approximately one month after discontinuing the ring. (See <a class="local">'Return of fertility'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Co-use of other vaginal products</strong> – The contraceptive ring can interfere with other female barrier contraceptives (ie, diaphragm, cervical cap, and female condom) but not most vaginal medications. One exception is that the SA/EE ring should not be used with oil-based vaginal products or medications. Tampons may be used during menses as they do not impact absorption of hormones from the ring. (See <a class="local">'Use with other vaginal devices and products'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Nuvaring [package insert]. Whitehouse Station, NJ. Merck and Co, Inc. 2001-2018. http://www.merck.com/product/usa/pi_circulars/n/nuvaring/nuvaring_pi.pdf (Accessed on May 17, 2018).</li><li class="breakAll">HALOETTE- etonogestrel and ethinyl estradiol insert, extended release. US Food and Drug Administration (FDA) approved product information. Revised November, 2022. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on December 09, 2022).</li><li class="breakAll">ELURYNG- etonogestrel and ethinyl estradiol ring. US Food and Drug Administration (FDA) approved product information. Revised May, 2022. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on December 09, 2022).</li><li><a class="nounderline abstract_t">Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39:233.</a></li><li><a class="nounderline abstract_t">van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72:168.</a></li><li class="breakAll">Annovera [package insert]. New York, NY. Manufactured for Population Council. August 2018. www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf (Accessed on August 13, 2018).</li><li class="breakAll">Hatcher R, Trussell J, Stewart F. Contraceptive Technology, 18th ed, Ardent Media, Inc, New York 2004.</li><li><a class="nounderline abstract_t">Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002; 100:585.</a></li><li><a class="nounderline abstract_t">Gupta N, Corrado S, Goldstein M. Hormonal contraception for the adolescent. Pediatr Rev 2008; 29:386.</a></li><li><a class="nounderline abstract_t">Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. Contraception 2016; 94:590.</a></li><li><a class="nounderline abstract_t">Dragoman M, Curtis KM, Gaffield ME. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes. Contraception 2016; 94:280.</a></li><li><a class="nounderline abstract_t">Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li><a class="nounderline abstract_t">Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li><a class="nounderline abstract_t">Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397.</a></li><li><a class="nounderline abstract_t">Lopez LM, Grimes DA, Gallo MF, et al. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2013; :CD003552.</a></li><li><a class="nounderline abstract_t">Killick S. Complete and robust ovulation inhibition with NuvaRing. Eur J Contracept Reprod Health Care 2002; 7 Suppl 2:13.</a></li><li><a class="nounderline abstract_t">Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001; 75:865.</a></li><li><a class="nounderline abstract_t">Dragoman M, Petrie K, Torgal A, et al. Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women. Contraception 2013; 87:432.</a></li><li><a class="nounderline abstract_t">Gilliam ML, Neustadt A, Kozloski M, et al. Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial. Obstet Gynecol 2010; 115:503.</a></li><li><a class="nounderline abstract_t">Archer DF, Merkatz RB, Bahamondes L, et al. Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials. Lancet Glob Health 2019; 7:e1054.</a></li><li><a class="nounderline abstract_t">Duijkers IJ, Klipping C, Verhoeven CH, Dieben TO. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. Hum Reprod 2004; 19:2668.</a></li><li class="breakAll">Nanda K. Contraceptive patch and vaginal contraceptive ring. In: Contraceptive Technology, 19th edition, Hatcher RA, Trussell, J, Nelson, AL, et (Eds), Ardent Media, New York 2007. p.271.</li><li><a class="nounderline abstract_t">Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006; 74:451.</a></li><li><a class="nounderline abstract_t">Schafer JE, Osborne LM, Davis AR, Westhoff C. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive. Contraception 2006; 73:488.</a></li><li><a class="nounderline abstract_t">Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 2006; 74:220.</a></li><li><a class="nounderline abstract_t">Bjarnadóttir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002; 186:389.</a></li><li><a class="nounderline abstract_t">Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004; 104:555.</a></li><li><a class="nounderline abstract_t">Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006; 21:2304.</a></li><li><a class="nounderline abstract_t">O'Connell KJ, Osborne LM, Westhoff C. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. Contraception 2005; 72:323.</a></li><li><a class="nounderline abstract_t">Polis CB, Phillips SJ, Curtis KM, et al. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. Contraception 2014; 90:360.</a></li><li><a class="nounderline abstract_t">Morrison CS, Chen PL, Kwok C, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med 2015; 12:e1001778.</a></li><li><a class="nounderline abstract_t">Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis 2015; 15:181.</a></li><li><a class="nounderline abstract_t">Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS 2016; 30:2665.</a></li><li><a class="nounderline abstract_t">Huang Y, Merkatz RB, Hillier SL, et al. Effects of a One Year Reusable Contraceptive Vaginal Ring on Vaginal Microflora and the Risk of Vaginal Infection: An Open-Label Prospective Evaluation. PLoS One 2015; 10:e0134460.</a></li><li><a class="nounderline abstract_t">De Seta F, Restaino S, De Santo D, et al. Effects of hormonal contraception on vaginal flora. Contraception 2012; 86:526.</a></li><li><a class="nounderline abstract_t">Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010; 93:2150.</a></li><li><a class="nounderline abstract_t">Westhoff C, Osborne LM, Schafer JE, Morroni C. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. Obstet Gynecol 2005; 106:89.</a></li><li><a class="nounderline abstract_t">Miller L, Verhoeven CH, Hout Ji. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol 2005; 106:473.</a></li><li><a class="nounderline abstract_t">Sulak PJ, Smith V, Coffee A, et al. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol 2008; 112:563.</a></li><li><a class="nounderline abstract_t">Barreiros FA, Guazzelli CA, Barbosa R, et al. Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects. Contraception 2010; 81:223.</a></li><li><a class="nounderline abstract_t">Schaffir J, Worly BL, Gur TL. Combined hormonal contraception and its effects on mood: a critical review. Eur J Contracept Reprod Health Care 2016; 21:347.</a></li><li><a class="nounderline abstract_t">Keyes KM, Cheslack-Postava K, Westhoff C, et al. Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States. Am J Epidemiol 2013; 178:1378.</a></li><li><a class="nounderline abstract_t">Wiréhn AB, Foldemo A, Josefsson A, Lindberg M. Use of hormonal contraceptives in relation to antidepressant therapy: A nationwide population-based study. Eur J Contracept Reprod Health Care 2010; 15:41.</a></li><li><a class="nounderline abstract_t">Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression. JAMA Psychiatry 2016; 73:1154.</a></li><li><a class="nounderline abstract_t">Massaro M, Di Carlo C, Gargano V, et al. Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. Contraception 2010; 81:209.</a></li><li><a class="nounderline abstract_t">Han L, Jensen JT. Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk? Obstet Gynecol Clin North Am 2015; 42:683.</a></li><li><a class="nounderline abstract_t">Selvan P, Piran P, Balucani C, et al. Stroke and Etonogestrel/Ethinyl Estradiol Ring (NuvaRing): Clinical, Radiological, and Prognostic Features. J Stroke Cerebrovasc Dis 2017; 26:608.</a></li><li><a class="nounderline abstract_t">Kolacki C, Rocco V. The combined vaginal contraceptive ring, nuvaring, and cerebral venous sinus thrombosis: a case report and review of the literature. J Emerg Med 2012; 42:413.</a></li><li><a class="nounderline abstract_t">Vo TL, Cook RM, Rondina MT, Kaplan D. Cerebral venous sinus thrombosis in the setting of combined vaginal contraception. Blood Coagul Fibrinolysis 2014; 25:183.</a></li><li><a class="nounderline abstract_t">Dinger J, Möhner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol 2013; 122:800.</a></li><li><a class="nounderline abstract_t">Sidney S, Cheetham TC, Connell FA, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2013; 87:93.</a></li><li><a class="nounderline abstract_t">Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception 2017; 95:130.</a></li><li><a class="nounderline abstract_t">Oddsson K, Leifels-Fischer B, de Melo NR, et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 2005; 71:176.</a></li><li><a class="nounderline abstract_t">Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod 2005; 20:557.</a></li><li><a class="nounderline abstract_t">Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001; 16:469.</a></li><li><a class="nounderline abstract_t">Merki-Feld GS, Hund M. Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Health Care 2007; 12:240.</a></li><li><a class="nounderline abstract_t">Abu Hashim H, Alsherbini W, Bazeed M. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 2012; 85:246.</a></li><li><a class="nounderline abstract_t">Cagnacci A, Ferrari S, Tirelli A, et al. Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study. Contraception 2009; 80:34.</a></li><li><a class="nounderline abstract_t">Guida M, Di Spiezio Sardo A, Bramante S, et al. Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners. Hum Reprod 2005; 20:1100.</a></li><li><a class="nounderline abstract_t">Morotti E, Casadio P, Guasina F, et al. Weight gain, body image and sexual function in young patients treated with contraceptive vaginal ring. A prospective pilot study. Gynecol Endocrinol 2017; 33:660.</a></li><li><a class="nounderline abstract_t">Guida M, Cibarelli F, Troisi J, et al. Sexual life impact evaluation of different hormonal contraceptives on the basis of their methods of administration. Arch Gynecol Obstet 2014; 290:1239.</a></li><li><a class="nounderline abstract_t">Roumen FJ, op ten Berg MM, Hoomans EH. The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands. Eur J Contracept Reprod Health Care 2006; 11:14.</a></li><li><a class="nounderline abstract_t">Stuart JE, Secura GM, Zhao Q, et al. Factors associated with 12-month discontinuation among contraceptive pill, patch, and ring users. Obstet Gynecol 2013; 121:330.</a></li><li class="breakAll">Nuva Ring Package Insert: Patient Information. Organon USA, Inc, 2008.</li><li class="breakAll">Nuvaring- etonogestrel and ethinyl estradiol insert, extended release. US Food and Drug Administration (FDA) approved product information. Revised May 30, 2017. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=017343fb-86c4-45ab-9c47-52cc5b9f3a02 (Accessed on June 23, 2017).</li><li><a class="nounderline abstract_t">Barreiros FA, Guazzelli CA, de Araújo FF, Barbosa R. Bleeding patterns of women using extended regimens of the contraceptive vaginal ring. Contraception 2007; 75:204.</a></li><li><a class="nounderline abstract_t">Guazzelli CA, Barreiros FA, Barbosa R, et al. Extended regimens of the vaginal contraceptive ring: cycle control. Contraception 2009; 80:430.</a></li><li><a class="nounderline abstract_t">Barreiros FA, Guazzelli CA, Barbosa R, et al. Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism. Contraception 2011; 84:155.</a></li><li class="breakAll">Etonogestrel and ethinyl estradiol insert, extended release. US Food &amp; Drug Administration (FDA) approved product information. Revised November, 2014. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on November 19, 2014).</li><li><a class="nounderline abstract_t">Mulders TM, Dieben TO, Bennink HJ. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod 2002; 17:2594.</a></li><li><a class="nounderline abstract_t">Simmons KB, Kumar N, Plagianos M, et al. Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study. Contraception 2018; 97:270.</a></li><li><a class="nounderline abstract_t">Sivin I, Mishell DR Jr, Alvarez F, et al. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. Contraception 2005; 71:122.</a></li><li><a class="nounderline abstract_t">Fraser IS, Weisberg E, Brache V, et al. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen. Contraception 2005; 72:40.</a></li><li><a class="nounderline abstract_t">Weisberg E, Brache V, Alvarez F, et al. Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen. Contraception 2005; 72:46.</a></li><li><a class="nounderline abstract_t">Jensen JT, Edelman AB, Chen BA, et al. Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study. Contraception 2018; 97:422.</a></li><li><a class="nounderline abstract_t">Archer DF, Thomas MA, Conard J, et al. Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone® and ethinyl estradiol. Contraception 2016; 93:58.</a></li><li><a class="nounderline abstract_t">RamaRao S, Obare F, Ishaku S, et al. Do Women Find the Progesterone Vaginal Ring Acceptable? Findings from Kenya, Nigeria, and Senegal. Stud Fam Plann 2018; 49:71.</a></li><li><a class="nounderline abstract_t">Massai R, Quinteros E, Reyes MV, et al. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. Contraception 2005; 72:352.</a></li><li><a class="nounderline abstract_t">RamaRao S, Clark H, Merkatz R, et al. Progesterone vaginal ring: introducing a contraceptive to meet the needs of breastfeeding women. Contraception 2013; 88:591.</a></li><li><a class="nounderline abstract_t">Nath A, Sitruk-Ware R. Progesterone vaginal ring for contraceptive use during lactation. Contraception 2010; 82:428.</a></li><li><a class="nounderline abstract_t">Massai R, Miranda P, Valdés P, et al. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception 1999; 60:9.</a></li><li class="breakAll">Caucus on New and Underused Reproductive Technologies. Progesterone-only vaginal ring: a technical brief. In: Reproductive Health Supplies Coalition, 2009.</li></ol></div><div id="topicVersionRevision">Topic 16682 Version 58.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.merck.com/product/usa/pi_circulars/n/nuvaring/nuvaring_pi.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nuvaring [package insert]. Whitehouse Station, NJ. Merck and Co, Inc. 2001-2018. http://www.merck.com/product/usa/pi_circulars/n/nuvaring/nuvaring_pi.pdf (Accessed on May 17, 2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.dailymed.nlm.nih.gov" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : HALOETTE- etonogestrel and ethinyl estradiol insert, extended release. US Food and Drug Administration (FDA) approved product information. Revised November, 2022. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on December 09, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.dailymed.nlm.nih.gov" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ELURYNG- etonogestrel and ethinyl estradiol ring. US Food and Drug Administration (FDA) approved product information. Revised May, 2022. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on December 09, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11020137" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102549" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102549" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102549" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12220783" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18977857" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hormonal contraception for the adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27263039" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26272309" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467319" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : U.S. Selected Practice Recommendations for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21477680" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Contraceptive failure in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633314" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Skin patch and vaginal ring versus combined oral contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12659397" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Complete and robust ovulation inhibition with NuvaRing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11334895" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312933" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177280" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31231065" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15333593" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15333593" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17157101" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16627032" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16904415" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904596" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339769" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A comparison between the vaginal ring and oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763008" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16246655" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25183264" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25612136" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25578825" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27500670" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26267119" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effects of a One Year Reusable Contraceptive Vaginal Ring on Vaginal Microflora and the Risk of Vaginal Infection: An Open-Label Prospective Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22520642" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effects of hormonal contraception on vaginal flora.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19328469" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994622" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135576" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Extended regimens of the contraceptive vaginal ring: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757653" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159178" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27636867" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Combined hormonal contraception and its effects on mood: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24043440" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20136568" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Use of hormonal contraceptives in relation to antidepressant therapy: A nationwide population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27680324" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Association of Hormonal Contraception With Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159176" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598309" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28041897" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Stroke and Etonogestrel/Ethinyl Estradiol Ring (NuvaRing): Clinical, Radiological, and Prognostic Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21945504" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The combined vaginal contraceptive ring, nuvaring, and cerebral venous sinus thrombosis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24477227" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cerebral venous sinus thrombosis in the setting of combined vaginal contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084537" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23083525" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27771476" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Nonoral combined hormonal contraceptives and thromboembolism: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15722066" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15539438" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11228213" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17763262" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067765" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19501213" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15608030" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28412867" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Weight gain, body image and sexual function in young patients treated with contraceptive vaginal ring. A prospective pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24981049" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sexual life impact evaluation of different hormonal contraceptives on the basis of their methods of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16546812" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23344283" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Factors associated with 12-month discontinuation among contraceptive pill, patch, and ring users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23344283" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Factors associated with 12-month discontinuation among contraceptive pill, patch, and ring users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23344283" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Factors associated with 12-month discontinuation among contraceptive pill, patch, and ring users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17303490" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Bleeding patterns of women using extended regimens of the contraceptive vaginal ring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19835716" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Extended regimens of the vaginal contraceptive ring: cycle control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21757057" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21757057" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12351535" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ovarian function with a novel combined contraceptive vaginal ring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097225" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone®(segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15707562" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15964291" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15964292" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29409834" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone®and estradiol: pharmacokinetics from a dose-finding study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26408374" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone®and ethinyl estradiol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29393513" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Do Women Find the Progesterone Vaginal Ring Acceptable? Findings from Kenya, Nigeria, and Senegal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16246661" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23769015" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Progesterone vaginal ring: introducing a contraceptive to meet the needs of breastfeeding women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20933116" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Progesterone vaginal ring for contraceptive use during lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10549447" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
